

## **Supplementary Information**

### **Spatially-graded hydrogels for preclinical testing of glioblastoma anticancer therapeutics**

S. Pedron<sup>1</sup>, H. Polishetty,<sup>1</sup> A. M. Pritchard<sup>1</sup>, B. P. Mahadik<sup>1</sup>, J. N. Sarkaria<sup>2</sup>, B. A. C. Harley<sup>1,3\*</sup>


## Supplementary Tables

**Table S1.**

Primer list for gene expression analysis (5' to 3'; forward and reverse).

<b>Gene</b>	<b>Primer sequence (5'-XXX-3')</b>	<b>Citation</b>
<b>CD44</b>	<i>Forward:</i> AGAAGGTGTGGGCAGAAGAA	1
	<i>Reverse:</i> AAATGCACCATTTCCTGAGA	
<b>VEGF</b>	<i>Forward:</i> CTACCTCCACCATGCCAAGT	2
	<i>Reverse:</i> GCAGTAGCTGCGCTGATAGA	
<b>MMP-2</b>	<i>Forward:</i> TCTCCTGACATTGACCTTGGC	2
	<i>Reverse:</i> CAAGGTGCTGGCTGAGTAGATC	
<b>HAS3</b>	<i>Forward:</i> CTC TAC TCC CTC CTC TAT ATG TC	3
	<i>Reverse:</i> AAC TGC CAC CCA GAT GGA	
<b>GAPDH</b>	<i>Forward:</i> CCTTCCACGATACCAAAGTTG	4
	<i>Reverse:</i> CCATGAGAAGTATGACAACAGCC	

Supplementary Figure



**Figure S1.** The metabolic activity, normalized to DMSO only control, of (a) GBM10 and (b) GBM12 PDX cells within GelMA hydrogels containing a linear gradient of matrix-immobilized HA. Day 7 results depict changes in metabolic activity seen after four days of exposure to fresh media following culture for three days in erlotinib (2, 10 and 100  $\mu\text{M}$ ). Day 10 results show subsequent changes in metabolic activity after re-exposure to a second dose of erlotinib (10  $\mu\text{M}$ ) for an additional three days. \*:  $p < 0.05$  compared to hydrogel region 1 (low HA content).

## References

1. G. Liu, X. Yuan, Z. Zeng, P. Tunici, H. Ng, I.R. Abdulkadir, L. Lu, D. Irvin, K.L. Black and J.S. Yu: Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. *Molecular Cancer* **5**, 67 (2006).
2. K.J. Hatanpaa, S. Burma, D. Zhao and A.A. Habib: Epidermal growth factor receptor in glioma: Signal transduction, neuropathology, imaging, and radioresistance. *Neoplasia (New York, N.Y.)* **12**, 675 (2010).
3. C. Wang, X. Tong and F. Yang: Bioengineered 3D brain tumor model to elucidate the effects of matrix stiffness on glioblastoma cell behavior using PEG-based hydrogels. *Molecular Pharmaceutics* **11**, 2115 (2014).
4. V. Serra, M. Scaltriti, L. Prudkin, P.J.A. Eichhorn, Y.H. Ibrahim, S. Chandarlapaty, B. Markman, O. Rodriguez, M. Guzman, S. Rodriguez, M. Gili, M. Russillo, J.L. Parra, S. Singh, J. Arribas, N. Rosen and J. Baselga: PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. *Oncogene* **30**, 2547 (2011).